References
- Berndt ER. The US pharmaceutical industry: why major growth in times of cost containment? Health Affairs 20(2), 100–114 (2001).
- Soumerai SB, McLaughlin TJ, Ross- Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl. I Med. 331, 650–655 (1994).
- Soumerai SB, Lipton HL. Computer-based drug utilization review—risk, benefit, or boondoggle? N Engl. I Med. 15(24), 1641–1645 (1995).
- Horn SD et al Intended and unintended consequences of HMO cost containment strategies: results from the managed care outcomes project. Am. I Managed Cate (March), 253–264 (1996).
- Lichtenberg E Do (more and better) drugs keep people out of hospitals. Am. Econ. Rev (May), 384–388 (1996).
- Lichtenberg FR. Are the benefits of drugs worth their cost? evidence from the 1996 MEPS. Health Affaits20(5), 241–251 (1996).
- ••Widely referenced article summarizingevidence on the value of pharmaceutical expenditures.
- Newhouse J. Medical care price indices: problems and opportunities. Academia Economic Papers 29(1), 1–65 (2001).
- •Outstanding summary of the shortcomings and opportunities in measuring changes in prices of medical services.
- Danzon P, Pauly M. Insurance and new technology: from hospitals to drugstore. Health Affairs20(5), 86–100 (2001).
- Triplett J. Accounting for Health Care: Integrating Price Index and Cost-Effectiveness Research. In: Measuring- the Prices of Medical Treatments. Triplett J (Ed.), Brookings Institution Press, Washington, DC, USA, 220–250 (1999).
- Schultze CL, Mackie C (Eds). At What Price? Conceptualizing and Nkasuting Cost-of-Living and Price Indexes National Academy Press, Washington, DC, USA (2002).
- Scitovsky AA.Changes in the costs of treatment of selected illnesses, 1951–65. Am. Econ. Rev 57(5), 1182–1195 (1967).
- •Seminal article dealing with cost of disease accounting.
- Scitovsky AA. Changes in the costs of treatment of selected illnesses, 1971–1981. Med. Care 23(12), 1345–1357 (1981).
- Dubois RVV, Chawla AJ, Neulusan CA, Smith MA, Wade S. Explaining drug spending trends: does perception match reality? Health Affairs 19(2), 231–239 (2000).
- •Provides additional details on the results of applying the decomposition approach described in this article.
- Merlis M. Explaining the growth in prescription drug spending: a review of recent studies. Prepared for the Department of Health and Human Services, Conference on Pharmaceutical Pricing Practices, Utilization and Costs. Washington, DC, USA (2000).
- ••An excellent review of several recentstudies of trends in pharmaceutical spending.
- Crown W, Treglia M. Specification issues in Econometric Models of Pharmacoeconomic Outcomes: An Application to Depression Treatment. Annual Meeting of the American Economics Association. Boston, MA, USA (2000).
- Garber A. Advances in Cost-Effectiveness Analysis of Health Interventions. Handbook of Health Economics 181–221 (2000).
- •Thorough discussion of methodological and conceptual issues associated with cost-effectiveness analysis.
- Ozminkowski R, Wang S, Marder W, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. PhatmacoEconomics 18(3), 253–264 (2000).
- Ozminkowski R, Wang S, Marder W Azzolini J. Short-run association between medical care expenditures and adherence to clinical practice guideline-based measures for diabetes. Value in Health3(s1), 29–38 (2000).
- Berndt ER, Bir A, Busch SH, Frank RG, Normand S-1T. The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexes. J. Health Econ. (In Press).
- Crown WH, Treglia M, Meneades L, White A. Long-term costs of treatment for depression: Impact of drug selection and guideline adherence. Value in Health 4(4), 295–307 (2001).
- Crown WH. Antidepressant selection and economic outcome: a review of methods and studies from clinical practice. BE fiychiatry179\(Suppl. 42), s18—s22 (2001).
- Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl. I Med. 342(25), 1887–1892 (2000).
- Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl. I Med. 342(25), 1878–1886 (2000).
Websites
- Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group, www.hcfa.gov/stats/nhe-oact/tables/t2.htm.
- HCFA, Highlights — National Health Expenditures, 1999. www.hcfa.gov/stats/ nhe-oact/hilites.htm
- Bureau of Labor Statistics. Bureau of Labor Statistics Handbook of Methods. Chapter 17, Consumer Price Index: www.b1s/gov/ opub/hom/homch17_a.htm.
- Swartz K. Be creative in consumer cost-sharing for pharmaceutical benefits. Inquiry Winter 1998/1999: www.inquiryjournal.org.